Sutro Biopharma

Sutro Biopharma has entered into a research collaboration with the FDA to develop reference materials that will improve regulatory standards and enhance analytical methods for antibody drug conjugate development.

Sutro Biopharma appointed Greg Chow as Chief Financial Officer effective June 2, 2025, bringing over 25 years of executive leadership experience in biotech finance and operations.

Novo Nordisk undergoes significant executive restructuring following the departure of EVP Camilla Sylvest, with rare disease leader Ludovic Helfgott taking over expanded commercial strategy responsibilities.

Sutro Biopharma (STRO) has been downgraded by multiple financial firms following the company's decision to discontinue its lead program luvelta.

Sutro Biopharma's luveltamab tazevibulin (luvelta) demonstrated a 32% overall response rate at the optimized dose of 5.2 mg/kg in platinum-resistant ovarian cancer patients, significantly outperforming the 13.8% rate seen at lower doses.

Ipsen secured FDA approval for Onivyde in first-line pancreatic cancer treatment and gained approvals for Iqirvo and Kayfanda in the U.S. and EU markets, expanding their therapeutic portfolio.

Sutro Biopharma's luvelta achieved a 32% objective response rate (ORR) in patients with platinum-resistant ovarian cancer (PROC) in the REFRαME-O1 trial.

Sutro Biopharma has commenced the REFRαME-P1 trial to evaluate Luvelta (luveltamab tazevibulin) in children under 12 with CBFA2T3::GLIS2 acute myeloid leukemia (AML).

Sutro Biopharma has begun the REFRαME-P1 trial, a registration-directed study of luveltamab tazevibulin (luvelta) for pediatric patients with CBF/GLIS AML.

Sutro Biopharma has commenced the REFRαME-P1 trial, a registration-enabling study of luveltamab tazevibulin (luvelta) for pediatric patients with CBF/GLIS AML.